Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding

This publication has 25 references indexed in Scilit:

• Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor
  International Journal of Immunopharmacology, 1994
• Expression and regulation of human and rat phosphodiesterase type IV isogenes
  FEBS Letters, 1994
• The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family
  Gene, 1993
• The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells
  International Journal of Immunopharmacology, 1993
• Modulation of TNFα and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors
  Inflammation Research, 1993
• Inhibition of CD44, CD45 and LFA-3 mediated cytokine release from human monocytes by SK&F 86002 and pentoxifylline
  International Journal of Immunopharmacology, 1993
• Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP‐specific phosphodiesterase
  FEBS Letters, 1992
• Interactions of formylmethionyl‐leucyl‐phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes Effects on superoxide release, inositol phosphates and cAMP
  FEBS Letters, 1989
• The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma
  Journal of Allergy and Clinical Immunology, 1981
• Continuous cultures of fused cells secreting antibody of predefined specificity
  Nature, 1975